CJC-1295

The CJC-1295 evidence base is built on three foundational papers from the original ConjuChem development program. Jetté et al. 2005 is the discovery paper — the in-vitro pharmacology, the DAC chemistry, the rat selection of CJC-1295 from a panel of three candidate bioconjugates. Teichman et al. 2006 is the Phase 1 human pharmacokinetic and pharmacodynamic study — two ascending-dose randomized placebo-controlled trials (28 and 49 days) in healthy adults aged 21 to 61, establishing the 5.8- to 8.1-day plasma half-life, the 2- to 10-fold single-dose GH elevation sustained for six days, the 1.5- to 3-fold IGF-1 elevation lasting nine to eleven days, and the maintenance of IGF-1 above baseline for up to 28 days with repeated dosing. Ionescu and Frohman 2006 is the mechanism paper — the demonstration that the multi-day albumin-anchored agonist preserves pulse architecture rather than collapsing it. Together those three papers, all from 2005-2006 and all funded by ConjuChem, are the core regulatory-grade evidence record on CJC-1295.

The development arc did not finish there. ConjuChem's CJC-1295 program never reached an FDA approval. Like other GH-secretagogue programs of the same era — Helsinn's ipamorelin development for postoperative ileus is the closest parallel — the molecule stalled at the pharmaceutical-development stage and migrated into the research-only and off-label space where it now lives. The original sponsor program encountered a serious safety event during a hypertension subindication trial that contributed to the development pause, though the event was not directly attributed to CJC-1295. No subsequent sponsor has carried the molecule into Phase 2 efficacy trials for the body-composition or GH-deficiency indications its pharmacology most plausibly suggests.

The most-cited practitioner application sits downstream of that absent pharmaceutical program: the CJC-1295 + Ipamorelin stack. The rationale is parallel-pathway engagement — CJC-1295 supplying tonic GHRH-receptor stimulus on somatotrophs while Ipamorelin contributes a clean ghrelin-receptor (GHS-R1a) pulse on top, producing a stronger combined GH response than either alone in animal pharmacology. The GH axis dossier walks the receptor stacking and the GH-secretagogue discontinuation playbook covers the cycling logic. The combination is widely used and rarely studied at the RCT level; no large randomized trial has tested the specific stack for the recomposition outcomes biohackers most care about. The recent Mendias and Awan 2026 Sports Medicine review places CJC-1295 explicitly within the "unapproved gray-market" framing alongside ipamorelin, BPC-157, GHK-Cu, MOTS-C, and TB-500, and flags the social-media-amplified placebo channel as a credible-journal concern for the broader category. The choice between the DAC and non-DAC forms is consequential, not cosmetic: the DAC variant produces sustained tonic IGF-1 elevation over weeks, while non-DAC Modified GRF (1-29) is used for pulse-timed per-injection dosing more akin to the sermorelin pharmacological window.

The honest framing has three parts. Regulatory status is research-only with no FDA approval and no active sponsor-led development program. The human evidence base is the small Teichman Phase 1 cohort — pharmacokinetic and pharmacodynamic in scope, not powered for efficacy or for uncommon adverse events. Everything else — receptor pharmacology, pulse-preservation mechanism, body-composition extrapolation — rests on rodent work, single-dose human PK studies, and class-level inference from GHRH-axis biology. Treat the Jetté-Teichman-Ionescu chronology as the load-bearing primary literature; treat the stacking, dosing, and chronic-use claims as practitioner extrapolation that the development program itself was designed but never completed to test.